A Phase 1/2 study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.

Disease Sites:

Pediatrics

Staging:

Phase I/II

Age Group:

Children

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Atezolizumab, Tiragolumab

Principal Investigator(s):

Borinstein, Scott

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

02-03-2023

Trial Type:

Treatment

Protocol ID:

COGPEPN2121

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available